Immunomedics Announces Results From Two Clinical Trials at Hematology Conference
Immunomedics, Inc. (Nasdaq: IMMU), today announced that two studies conducted by outside investigators that involved the Company's antibody drug candidates were presented at the 53^rd Annual Meeting of the American Society of Hematology.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.